NEW YORK, NY / ACCESSWIRE / January 14, 2023 / WHY: Rosen Law Firm, a global investor rights law firm, is reminding buyers of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) securities between December 6, 2021 and September 22, 2022, both dates inclusive (the “Collection Period”), that Important February 3, 2023 deadline for the plaintiff.
SO WHAT: If you purchased Spectrum Securities during the Class Period, you may be entitled to compensation without payment of expenses or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To participate in the Spectrum Class Action go to https://rosenlegal.com/submit-form/?case_id=9455 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action. A class action lawsuit has already been filed. If you want to appear as lead plaintiff, you must call the court by February 3, 2023 at the latest. A lead plaintiff is a representative party acting on behalf of other group members in conducting the litigation.
WHY ROSES LAW: We encourage investors to select qualified advisors with a track record in leadership positions. Frequently, companies that issue notices do not have comparable experience, resources, or meaningful recognition from peers. Many of these law firms do not actually conduct securities class actions, but are merely intermediaries who refer clients or work with law firms that actually conduct the cases. Be wise in choosing a lawyer. The Rosen law firm represents investors worldwide and focuses its practice on securities class actions and shareholder derivatives litigation. Rosen Law Firm has achieved the largest-ever settlement of a securities class action lawsuit against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named Titan of Plaintiffs’ Bar by Act360. Many of the firm’s attorneys are recognized by Lawdragon and Super Lawyers.
CASE DETAILS: The lawsuit alleges that throughout the class period, the defendants made numerous materially false and misleading statements and/or omissions regarding their drug candidate poziotinib or “pozi.” The defendants were conducting a phase 2 clinical trial called ZENITH20. The ZENITH20 study was an ongoing, multicenter, multicohort-free, open-label, activity estimation study to evaluate the antitumor efficacy, safety, and tolerability of Pozi in patients with previously treated locally advanced or metastatic non-small cell lung cancer. In addition, the Complaint alleges that during the Class Period, the Defendants maintained that the safety and efficacy data from the ZENITH20 study were positive and based on these positive results, they initiated a required confirmatory Phase 3 study . However, this was not true. As the truth trickled out over several days, the lawsuit alleges that investors suffered heavy losses.
To participate in the Spectrum Class Action go to https://rosenlegal.com/submit-form/?case_id=9455 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action.
No class was certified. Until a class is certified, you will not be represented by an attorney unless you retain one. You can select a lawyer of your choice. You can also remain absent and do nothing at this point. An investor’s ability to participate in a potential future recovery is not contingent on its serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
lawyer advertising. Previous results do not guarantee a similar result.
——————————-
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Law Firm of Rosen, PA
275 Madison Avenue, 40th floor
New York, New York 10016
Phone: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
SOURCE: Rosen PA Law Firm
View source version on accesswire.com:
https://www.accesswire.com/735270/ROSEN-NATIONAL-TRIAL-LAWYERS-Encourages-Spectrum-Pharmaceuticals-Inc-Investors-with-Losses-to-Secure-Counsel-Before-Important-Deadline-in-Securities- Class Action SPPI